Modern medicine should help patients feel better, not worse. At LimeRiver, we believe in the Hippocratic principle of "do no harm." We believe this is inherent to the innovative True Human™ antibody medicines we are developing.
True Human™ antibodies move beyond the idea that effective medicines must come with toxicity or harmful side effects. By utilizing the body's natural immune system, LimeRiver develops therapies that help you heal and feel better.
Rooted in the Hippocratic tradition — every therapy we develop prioritizes patient safety above all else.
True Human™ antibodies work with your body's own immune system — not against it.
Challenging the assumption that effective treatment must come with harmful side effects.
LimeRiver Biotechnologies Inc. is committed to advancing healthcare, agriculture, and environmental sustainability through cutting-edge research.
We bring together top scientists, engineers, and innovators to solve real-world biological challenges.
Our experienced leaders bring decades of expertise in biotechnology, immunology, and pharmaceutical development.
Founder, Chairman of the Board, Scientific Advisor
John Simard graduated from the biochemistry program at the University of Saskatchewan in 1992 and went on to study immunology at the prestigious Department of Medical Biophysics, University of Toronto. In 1994, Simard left graduate studies to work with the Amgen Research Institute, where he collaborated with acclaimed scientist Tak W. Mak to write a textbook of immunology and co-author numerous publications.
Simard co-authored a seminal manuscript with Nobel Laureate Rolf Zinkernagel on the biology of cytotoxic T lymphocytes, which led to Simard launching CTL ImmunoTherapies Corp. in Toronto in 1997. Mr. Simard created a partnership between CTL ImmunoTherapies and Alfred Mann's MiniMed Inc. to use the latter's technology as a delivery system for cancer vaccines.
In 2001, Mr. Simard merged Allecure and CTL Immunotherapies, together with a third company, to create MannKind Corp. Mr. Simard served on the board of MannKind and was President of its Immunotherapy division until 2002.
In 2005, Mr. Simard founded LimeRiver. In 2015, he led LimeRiver through an initial public offering without conventional underwriting. In 2019, he orchestrated the sale of a True Human antibody for cash and milestones totaling $1.35 billion. Simard is the inventor of over 300 issued and pending patents relating to immunotherapies for cancer and infectious disease.
Chief Scientific Officer, Interim Chief Executive Officer
Dr. Shivaswamy was appointed as the Company's Chief Scientific Officer in November 2017. As CSO, she oversees all scientific and technical operations related to research and development and GMP production of antibodies.
She previously served as Vice President of Research and Development since January 2015, leading teams involved in various R&D projects at LimeRiver, including Antibody Discovery, Cell Line Development, and pre-clinical toxicology and efficacy studies using animal models.
Dr. Shivaswamy has been with the company since 2009. Prior to joining LimeRiver, she was a postdoctoral researcher at the Center for Systems and Synthetic Biology at the University of Texas at Austin. She holds a Ph.D. in Molecular Biology from the Center for Cellular and Molecular Biology, India.
Senior Vice President of Clinical Operations and Analytical Quality
Dr. Wu has served LimeRiver as VP of Quality Control since July 2017. She oversees quality control functions supporting CMC and clinical operations, including in-process, release, and stability testing of API and drug products, microbiology and environmental monitoring, analytical development and validation, raw material testing, and clinical pharmacokinetics and pharmacodynamics.
She joined LimeRiver in 2011 as a Senior Scientist in Analytical Development. Dr. Wu holds a B.S. in Biochemistry and Molecular Biology from Peking University (China) and a Ph.D. in Biochemistry from Texas A&M University. She completed postdoctoral research at the University of Texas Southwestern Medical Center.
Vice President of Quality
Ms. Gonzalez has served as Vice President of Quality since February 2008. Before joining LimeRiver, she was Director of Quality at Carbomedics, where she held multiple roles, including Director of R&D, Director of Manufacturing (Mechanical Heart Valve), and Director of Tissue Valve and Quality.
Vice President of Manufacturing
Dr. Cavalier, a Ph.D.-level Protein Biochemist with postdoctoral training, oversees all aspects of cGMP manufacturing for LimeRiver's True Human™ monoclonal antibody platform using single-use methodologies.
He manages manufacturing personnel and daily production operations to ensure timely delivery of high-quality drug products. Before joining LimeRiver, Dr. Cavalier was a Postdoctoral Fellow at the University of Maryland School of Medicine. He earned his Ph.D. in Biochemistry from Louisiana State University.
Board of Directors
Key milestones in LimeRiver's mission to transform biotechnology.
John Simard incorporates LimeRiver with $1M in seed capital in Vancouver, Canada. Files IP for diagnosis, treatment, and prevention of vascular disorders using antibodies derived from natural human immunity.
LimeRiver USA, Inc. is established with laboratories and manufacturing infrastructure in Austin, Texas to facilitate clinical development of its therapies.
LimeRiver goes public through an initial public offering completed without conventional underwriting — a first in biotechnology.
Dr. Sushma Shivaswamy appointed Chief Scientific Officer, strengthening the company's R&D and GMP antibody production capabilities.
John Simard orchestrates the sale of a True Human™ antibody for cash and milestones totaling $1.35 billion — validating the platform's commercial potential.
LimeRiver continues to pioneer discovery and development of antibody therapeutics based on its True Human™ technology, with over 300 issued and pending patents.
We've got some big things we're working on and are looking for smart, talented people to join our team. All of our current job openings are in-house at our headquarters in beautiful Austin, Texas.
At LimeRiver, we believe in fostering a positive and inclusive work environment. Our employee benefits package is designed to support your well-being and professional growth.
Comprehensive medical, dental, and vision insurance.
Competitive salaries, retirement plans, and stock options.
Generous paid time off, flexible work hours.
Opportunities for training, conferences.
Regular social events, team outings, and company team sports activities.
Employee promotion opportunities and incentives for outstanding performance.
Work on molecular biology and drug innovation.
Support lab operations and experiments.
Analyze biological datasets and research insights.
Provide exceptional support and communication to clients and partners.
Accurately manage and input critical data across systems.
Support human resources operations and employee experience.